Navigation Links
Max Neeman International Completes Targeted Enrollment of 15,000 for Large Ph IV Study
Date:4/12/2011

RESEARCH TRIANGLE PARK, N.C., April 12, 2011 /PRNewswire/ -- Max Neeman meets enrollment and timeline of 15,000 for a large, Phase IV metabolic disorder trial across 1200 sites throughout India. As a leading Indian CRO, the company has completed multiple Phase IV studies for global sponsors with thousands of patients successfully enrolled.  A 30,000 patient enrollment study across 1500 sites is currently in-process with four more in the pipeline.

(Logo: http://photos.prnewswire.com/prnh/20110105/CL25129LOGO)

Current Ph IV success and activities are due to a specific business model Max Neeman created for such 'Observational studies' based on over 10 years of experience. Segments of the business model include: zonal stratification of >1000 sites and SOPs to improve quality of patient data retrieved in large studies. More than 30 CSRs have been developed to date.

The prevalence of diabetes in India is only second to China with 50.8 million people diagnosed with the disease and expected to rise steeply in the coming years. More large Ph IV studies are predicted and Max Neeman is prepared with a Ph IV strategy that is a combination of operational excellence (via Six Sigma practices), dedicated and trained project management teams, flexible delivery models, a customized approach and integrated technology. All these combine to deliver positive results on a customer's objective in a swift and cost effective manner.

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India and the clinical research arm of healthcare conglomerate, Max India.  Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP
'/>"/>

SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Max Neeman Develops Innovative Approach for Rare Disease Studies
2. Max Neeman International ISO 27001:2005 Certified for Information Security Management Systems
3. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
4. Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
5. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
6. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
7. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
8. PRA International Experts to Speak at Drug Safety Conference
9. HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual Meeting
10. Mauna Kea Technologies Announces Highlights of Third International Conference of Cellvizio Users (ICCU)
11. Two New U.S. Patents Issued to Dyadic International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WASHINGTON , Jan. 15, 2014 AARP Foundation today ... support older adults suffering from the severe cold weather that ... are committed to helping those in need; so to support ... dollar-for-dollar contributions up to $250,000, which could mean up to ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Radial Strength, FlexibilityHOUSTON, March 18 IDEV Technologies ... and marketing of minimally invasive technologies, announced today ... has approved an investigational device exemption (IDE) for ... a novel stent platform designed for the treatment ...
... March 18 ULURU Inc. (NYSE Alternext: ULU) ... diabetic foot ulcers, and data on the use of ... presented at the annual DFCon Global Meeting in Los ... presented on posters that will be on display during ...
Cached Medicine Technology:U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies' SUPERA Peripheral Stent 2ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 2ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009 3
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... YORK April 17, 2014 EcoHealth Alliance, a ... health issues, published a comprehensive review today examining the ... Marburg virus. The review calls for improved global surveillance ... as the recent outbreak of Ebola in West Africa ... the countries of Guinea and Liberia. According to ...
(Date:4/17/2014)... by Cesar A. Arias, M.D., Ph.D., at The University ... identified a new superbug that caused a bloodstream infection ... April 17 issue of The New England Journal ... of a class of highly-resistant bacteria known as methicillin-resistant ... major cause of hospital and community-associated infections. The superbug ...
(Date:4/17/2014)... WINSTON-SALEM, N.C. April 17, 2014 Meaningful ... from advanced cancer of the abdomen when treated ... HIPEC, according to a first-of-its-size analysis by physicians ... Forest Baptist has the largest reported, single-center experience ... Edward A. Levine, M.D., and analysis of 20 ...
(Date:4/17/2014)... study has found that India,s shocking rates of suicide ... who are clinging to tiny smallholdings less than ... such as cotton and coffee, that are highly susceptible ... range of previous case studies that point to a ... the ,liberalisation, of the nation,s economy during the 90s. ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3
... Pressure-Lowering Device to be Available at 1,440 Stores ... April 28 InterCure Ltd., a medical,device company ... (TASE: INCR),today announced that its RESPeRATE(R) hypertension treatment ... into,full-scale retail distribution within the United Kingdom this ...
... motherhood more than doubled in six years among teenage ... published in the May issue of Diabetes Care. ... at gestational diabetes (diabetes that develops during pregnancy, then ... the largest and most diverse study to examine pre-pregnancy ...
... they take, changes in biological clock put many at risk ... Many older adults don,t get enough sleep, which can increase ... disease and diabetes, says the American Academy of Sleep Medicine. ... disturbed sleep and waking up tired every day aren,t a ...
... osteoporosis, , , SATURDAY, April 26 (HealthDay News) -- While ... harmless enough, recent research suggests that those tasty drinks ... enough evidence that high consumption of soda and carbonated ... children, and that,s a real concern and people should ...
... Irvine, Calif., April 25, 2008 -- Advance directives, or ... life-sustaining treatment preferences often change without people being aware ... by UC Irvine researchers Peter Ditto and Elizabeth Loftus. ... in the discrepancy between an individual,s true preferences for ...
... PRINCETON, N.J., April 25 Medarex, Inc.,(Nasdaq: ... BMY ) today announced,that, after meeting with the ... delay the Biologics License Application (BLA) submission for,ipilimumab, ... The FDA has requested additional overall survival (OS),data ...
Cached Medicine News:Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 2Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 3Health News:InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group 4Health News:Kaiser Permanente study finds diabetes doubling before motherhood 2Health News:Kaiser Permanente study finds diabetes doubling before motherhood 3Health News:Elderly More Likely to Battle Sleep Disorders 2Health News:Cola May Be Bad to the Bones 2Health News:Cola May Be Bad to the Bones 3Health News:Study shows false memories complicate end-of-life treatment decisions 2Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 2Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 3Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 4Health News:Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab 5
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
Fulgurating Electrode, 2 F...
ACMI S-Series Cystourethroscope Systems: Precision instruments designed for superior optical recognition, accurate control, and exceptional durability during steam autoclave sterilization....
Medicine Products: